Genomic Health (GHDX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance
August 2, 2016 4:05 PM EDTREDWOOD CITY, Calif., Aug. 2, 2016 /PRNewswire/ --Â Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2016.
Total revenue was $82.0 million in the second quarter of 2016 and includes $0.1 million in contract revenue, compared with $70.6 million in the second quarter of 2015, an increase of 16 percent.
U.S. product revenue was $69.6 million in the second quarter of 2016, an increase of 15 percent, compared with the same period in the prior year. Â Prostate test revenue in the U.S. of $2.3 million contributed to approximately 3 percent of the year-over-year... More
